Avastin Lung Cancer Launch To Bolster Roche’s China Sales
This article was originally published in PharmAsia News
Roche has launched Avastin for lung cancer in China, marking the expanded use of one of the company’s best-selling therapies globally to treat a prevalent cancer type in the country, where new product approvals have been few and far between.
You may also be interested in...
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.
China is nearing the finish line in the coronavirus vaccines race with just “the last kilometer to go”, and its government is already negotiating with the WHO for potential global supplies.